SURFACTANT
RESEARCH
NOVEMBER 30 – DECEMBER 4, 2020
“Clarifying the surfactant role in neonates,
children and adults with respiratory failure”
MONDAY – NOVEMBER 30, 2020
13:30 – 15:30 CETHow can we enhance surfactant efficiency?
Chairs: D. De Luca, L. Touqui (Paris, France)
Greetings: Daniele De Luca (MD, PhD),
The role of budesonide – N. Hillman (St.Louis, MO – USA)
15 min discussion
The role of varespladib and sPLA2 inhibitors – G. Lambeau (Nice, France)
15 min discussion
The role of hu-r-SP-D – P. Kingma (Cincinnati, OH – USA)
15 min discussion
17:00 – 18:30 CETHow to study surfactant effect on the bedside in PICU/NICU?
Chair: P.Rimensberger (Geneve, Switzerland), M. V. Fraga (Philadelphia, USA)
EIT – A. van Kaam (Amsterdam, Netherlands)
15 min discussion
Lung ultrasound – D. De Luca (Paris, France)
15 min discussion
Lung MRI – P. Kingma (Cincinnati, OH – USA)
15 min discussionr
TUESDAY – DECEMBER 1, 2020
14:00 – 16:30 CETAre there alternative way to deliver surfactant?
Chair: D. De Luca (Parigi, France) – G. Mendes Sant’Anna (Montréal, Canada)
Non-bronchoscopic bronchoalveolar lavage – G. Lista (Milan, Italy)
15 min discussion
Bronchoscopic broncho-alveolar lavage – S. Nosal (Martin, Slovakia)
15 min discussion
Supraglottic devices – D. Trevisanuto (Padua, Italy)
15 min discussion
Nebulization – F. Bianco (Parma, Italy)
15 min discussion
17:00 – 19:00 CETOpen questions in surfactant biology
Chair: G. Lambeau (Nice, France)
What is the interaction between surfactant and secretory phospholipases? – D. Hite (Cincinnati, OH – USA)
10 min discussion
What is the best animal model to study surfactant injury/treatment? – F. Salomone (Parma, Italy)
10 min discussion
Can surfactant really be a drug carrier? – J. Perez-Gil (Madrid, Spain)
10 min discussion
Can we distinguish between endogenous and exogenous surfactant metabolism? – V. P. Carnielli (Ancona, Italy)
10 min discussion
WEDNESDAY – DECEMBER 2, 2020
14:00 – 16:30 CETWhat is what in surfactant biology?
Chair: E. Lopez-Rodriguez (Hannover, Germany) – G. Lambeau (Nice, France)
cPLA2 or sPLA2? What is the most important phospholipase in lung injury? – M. Murakami (Tokyo, Japan)
10 min discussion
What is the effect of oxidative stress on surfactant? – M. Vento (Valencia, Spain)
10 min discussion
What may be the best surfactant composition? – J. Perez-Gil (Madrid, Spain)
10 min discussion
What is the effect of hypothermia on surfactant? – D. De Luca (Paris, France)
10 min discussion
17:00 – 18:30 CETSurfactant and ARDS
Chair: MV. Ranieri (Bologna, Italy), P. Rimensberger (Geneve, Switzerland)
The importance of the various subtypes of ARDS – N. Yehya (Philadelphia, USA)
10 min discussion
Surfactant composition changes in ARDS – A. Gunther (Giessen, Germany)
10 min discussion
Future directions for surfactant therapy in NARDS and PARDS – D. De Luca (Paris, France)
10 min discussion
THURSDAY – DECEMBER 3, 2020
14:00 – 16:00 CETBedside biological test to evaluate surfactant status
Chair: F. Salomone (Parma, Italy)
Spectroscopic lipid analysis – H. Verder (Holbaek, Denmark)
15 min discussion
Surfactant adsorption test – C. Autilio (Madrid, Spain)
15 min discussion
Lamellar body count – D. De Luca (Paris, France)
15 min discussion
Stable microbubble test – H. Fiori (Porto Alegre, Brasil)
15 min discussion
17:00 – 18:30 CETARDS: Surfactant system as biomarker
Chair: M. Lewin (Corte Madera, CA – USA) – D. De Luca (Paris, France)
Phospholipases as biomarkers for ARDS – M. Lekka (Ioannina, Greece)
10 min discussion
Surfactant proteins as biomarker for PARDS – H. Flori (Ann Arbor, MI – USA)
10 min discussion
Biomarker for ARDS or biomarker for VILI in ARDS patients? – MV. Ranieri (Bologna, Italy)
FRIDAY – DECEMBER 4, 2020
14:00 – 15:30 CETCompassionate surfactant therapies in ARDS
Chair: M. Di Nardo (Rome, Italy), G. Conti (Rome, Italy)
Use of surfactant therapies for NARDS – D. De Luca (Paris, France)
10 min discussion
Use of surfactant therapies for PARDS – M. Piastra (Rome, Italy)
10 min discussion
Use of surfactant for ARDS – S. Busani (Modena, Italy)
10 min discussion
16:30 – 18:10 CETIs there a role for surfactant in COVID19?
Chair: M. Antonelli (Rome, Italy) – D. De Luca (Paris, France)
COVID19 is not (always) a “real” ARDS – L. Gattinoni (Göttingen, Germany)
10 min discussion
What really is respiratory failure due to COVID19? – G. Iotti (Pavia, Italy)
10 min discussion
What really is COVID19 in PICU? – P. Tissieres (Paris, France)
10 min discussion
Closing remarks: Daniele De Luca (MD, PhD)
ORGANIZED BY:
Daniele De Luca (MD, PhD)
France
ENDORSED BY
Scientific Committee
Massimo Antonelli
Roma, Italy
Giorgio Conti
Roma, Italy
Heide Flori
Ann Arbor – MI, USA
Anton van Kaam
Amsterdam, Netherlands
Gerard Lambeau
Nice, France
Salvatore M. Maggiore
Pescara, Italy
Ram Ramanatham
Los Angeles – CA, USA
Pierre Tissieres
Paris, France
David Tingay
Melbourne, Australia
Lhousseine Touqui
Paris, France